

-IMPORTANT:

If you are in doubt about the contents of this announcement and notice or as to the action to be taken, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser.

The Stock Exchange of Hong Kong Limited, Hong Kong Securities Clearing Company Limited and the Securities and Futures Commission (“SFC”) take no responsibility for the contents of this announcement and notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement and notice.

iShares Asia Trust

a Hong Kong unit trust authorised under

Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong¹

iShares FTSE A50 China ETF (HKD Counter Stock Code: 2823) (RMB Counter Stock Code: 82823)

iShares Hang Seng TECH ETF (HKD Counter Stock Code: 03067) (USD Counter Stock Code: 09067)

sub-funds of the iShares Asia Trust

(the “**Sub-Funds**”)

Distribution Announcement

BlackRock Asset Management North Asia Limited, as manager of iShares Asia Trust, announced today that the final distribution payment of the distribution payment per unit for the Sub-Funds shall be as follows:

Name of Sub-Funds	Distribution payment per unit
iShares FTSE A50 China ETF	RMB 0.27
iShares Hang Seng TECH ETF	-

The ex-distribution date for the Sub-Fund is 18 December 2020 and the record date is 21 December 2020. The payment date of the distribution will be on 28 December 2020.

The Manager accepts responsibility for the accuracy of the information contained in this Announcement.

If you have any questions concerning this Announcement, please contact us on +852 3903 2823.

**BlackRock Asset Management North Asia Limited
as Manager of the Sub-Funds**

Hong Kong, 23 November 2020

¹ *SFC authorisation is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.*